WHIM Syndrome (CXCR4 Gain-of-Function)
A rare inherited immunodeficiency causing chronic neutropenia, recurrent warts, low antibody levels, and frequent infections due to mutations in the CXCR4 gene.
- Targeted oral therapy approved
- Genetic testing confirms diagnosis
- Manageable with specialist care
- Most Common In
- Any age; autosomal dominant inheritance
- Key Hallmark
- Chronic neutropenia with myelokathexis
- Affected Gene
- CXCR4
- Advanced Therapies
- CXCR4 antagonist oral therapy
What Is WHIM Syndrome?
WHIM Syndrome is a rare, inherited immunodeficiency named for its core features: Warts, Hypogammaglobulinemia, Infections, and Myelokathexis. It is caused by gain-of-function mutations in the CXCR4 gene, which encodes a receptor that normally helps regulate how white blood cells move from the bone marrow into the bloodstream.
In WHIM syndrome, the mutated receptor signals too strongly, trapping mature neutrophils inside the bone marrow โ a phenomenon called myelokathexis โ and resulting in low circulating neutrophil counts despite the marrow appearing full of mature cells. This leads to recurrent bacterial infections, along with low antibody (immunoglobulin) levels and a striking susceptibility to human papillomavirus (HPV)-related warts that can be extensive and difficult to treat.
WHIM syndrome is inherited in an autosomal dominant pattern, though sporadic (de novo) cases also occur. Severity varies between individuals, and some patients are not diagnosed until adulthood despite lifelong symptoms.
Clinical Variants
WHIM syndrome is classified primarily by the specific CXCR4 mutation and the prominence of its clinical features.
Symptoms and Warning Signs
WHIM syndrome typically presents with a combination of recurrent infections, low blood counts, and characteristic skin findings.
Causes and Risk Factors
WHIM syndrome is a genetic disorder; it is not caused by lifestyle or environmental factors, though HPV exposure determines wart development.
Diagnosis and Investigations
Diagnosis relies on recognizing the characteristic combination of neutropenia, infections, low antibodies, and warts, confirmed by genetic testing.
Disease Severity Stratification
WHIM syndrome is not formally staged, but clinicians classify severity based on infection frequency, neutrophil counts, and wart burden.
Standard Treatment Approach
Treatment for WHIM syndrome historically focused on managing infections and warts individually, but targeted therapy now addresses the underlying CXCR4 defect.
Advanced and Emerging Treatment Options
Targeted oral therapy directed at the CXCR4 pathway represents a major advance for WHIM syndrome, moving beyond purely supportive treatment.
Targeted Therapy
CXCR4 antagonist (e.g. mavorixafor)
An oral medication that blocks excess CXCR4 signaling, helping mobilize neutrophils and lymphocytes from the bone marrow and reduce infection frequency.
Immunoglobulin Replacement
Subcutaneous or intravenous immunoglobulin
Supports antibody-mediated protection in patients with significant hypogammaglobulinemia.
Precision Medicine
Genotype-informed monitoring
Specific CXCR4 mutation type may help predict disease course and inform individualized monitoring plans.
Biomarkers and Precision Testing
Blood count, immunoglobulin, and genetic markers are central to diagnosing and monitoring WHIM syndrome.
When a Second Opinion May Be Important
Because WHIM syndrome is rare and can be mistaken for other causes of neutropenia or recurrent warts, specialist input is valuable.
Clinical Trials and Research
Prognosis and Key Outcome Factors
With appropriate management, including targeted CXCR4 antagonist therapy where available, many people with WHIM syndrome can achieve substantial improvement in infection frequency and quality of life.
Supportive Care and Living With WHIM Syndrome
Living with WHIM syndrome involves coordinated infection prevention, dermatologic care, and long-term monitoring.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with WHIM syndrome connect with specialists experienced in primary immunodeficiencies, coordinate medical report review, and explore access to targeted CXCR4 antagonist therapy.
Get a free case reviewFrequently Asked Questions
WHIM syndrome is a rare inherited immunodeficiency caused by CXCR4 gene mutations, leading to chronic neutropenia, recurrent infections, low antibody levels, and extensive warts.
Early signs often include recurrent bacterial infections, chronic low neutrophil counts found incidentally, and unusually extensive or persistent warts.
WHIM stands for Warts, Hypogammaglobulinemia, Infections, and Myelokathexis โ the core features of the syndrome.
Yes โ WHIM syndrome is typically inherited in an autosomal dominant pattern, though some cases arise from new mutations.
Treatment includes infection prevention, immunoglobulin replacement, wart management, and targeted CXCR4 antagonist therapy that addresses the underlying defect.
Yes โ because symptoms can be mild or attributed to other causes, many patients are not diagnosed until adulthood.
Rarely, HPV-related lesions in WHIM syndrome can undergo malignant transformation, which is why regular dermatologic monitoring is recommended.
There is no cure, but targeted CXCR4 antagonist therapy can significantly reduce infections and improve blood counts for many patients.
Genetic counseling and testing are recommended for close relatives, since symptom severity can vary widely within the same family.
Yes. CancerFax can help coordinate medical report review, connect patients with specialists experienced in primary immunodeficiencies, support second opinion requests, and facilitate access to targeted therapies, including cross-border coordination when needed.
Get Expert Guidance on WHIM Syndrome Management
Our team can help you connect with specialists experienced in primary immunodeficiencies for diagnosis confirmation and treatment planning.